Identification of a novel synthetic lethal vulnerability in non-small cell lung cancer by co-targeting TMPRSS4 and DDR1
Villalba M, Redin E, Exposito F, Pajares MJ, Sainz C, Hervas D, Guruceaga E, Diaz-Lagares A, Cirauqui C, Redrado M, Valencia K, de Andrea C, Jantus-Lewintre E, Camps C, Lopez-Lopez R, Lahoz A, Montuenga L, Pio R, Sandoval J, Calvo A. Identification of a novel synthetic lethal vulnerability in non-small cell lung cancer by co-targeting TMPRSS4 and DDR1. Scientific Reports 2019, 9: 15400. PMID: 31659178, PMCID: PMC6817908, DOI: 10.1038/s41598-019-51066-3.Peer-Reviewed Original ResearchTargeting of TMPRSS4 sensitizes lung cancer cells to chemotherapy by impairing the proliferation machinery
Exposito F, Villalba M, Redrado M, de Aberasturi AL, Cirauqui C, Redin E, Guruceaga E, de Andrea C, Vicent S, Ajona D, Montuenga LM, Pio R, Calvo A. Targeting of TMPRSS4 sensitizes lung cancer cells to chemotherapy by impairing the proliferation machinery. Cancer Letters 2019, 453: 21-33. PMID: 30905815, DOI: 10.1016/j.canlet.2019.03.013.Peer-Reviewed Original ResearchConceptsTumor growthOverexpression of TMPRSS4Novel therapeutic targetSubcutaneous tumor growthHigh mortality rateLung cancer cellsG2/M phasePoor prognosisTumor engraftmentChemotherapy agentsTherapeutic targetMortality rateNSCLCNovel targetTMPRSS4Cancer cellsDownregulation of genesVivo assaysBiological effectsM phaseKD cellsMolecular mechanismsDownregulationCellsCell cycle